Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 203-215 , April 2010

Gastrointestinal and liver side effects of drugs in elderly patients

  • Konstantinos Triantafyllou, MD, PhD (Lecturer in Gastroenterology)

      Affiliations

    • Hepatogastroenterology Unit, 2nd Department of Internal Medicine – Propaedeutic, Attikon University General Hospital, Medical School, Athens University, Chaidari, Greece
    • ,
  • Jiannis Vlachogiannakos, MD, PhD (Assistant Professor in Gastroenterology)

      Affiliations

    • Hepatogastroenterology Division, 1st Department of Internal Medicine – Propaedeutic, Laiko General Hospital of Athens, Medical School, Athens University, Athens, Greece
    • ,
  • Spiros D. Ladas, MD, PhD (Professor in Gastroenterologoly)

      Affiliations

    • Hepatogastroenterology Division, 1st Department of Internal Medicine – Propaedeutic, Laiko General Hospital of Athens, Medical School, Athens University, Athens, Greece
    • Corresponding Author InformationCorresponding author. 1st Department of Internal Medicine – Propaedeutic, Laiko General Hospital of Athens, Ag. Thoma 17, 11527, Athens, Greece. Tel.: +30 210 7456261; fax: +30 210 7791839.

References 

  1. Hall KE, Proctor DD, Fisher L, Rose S. American Gastroenterological Association Future Trends Committee Report: effects of aging of the population on gastroenterology practice, education, and research. Gastroenterology. 2005;129:1305–1338
  2. The United Nations Department of Economic and Social Affairs . Population Division. World Population Ageing 2009, ESA/P/WP/212. Available at: http://www.un.org/esa/population/publications/WPA2009/WPA2009_WorkingPaper.pdfDecember 2009;
  3. Federal Interagency Forum on aging-related statistics. Older Americans 2008: key indicators of well-being. Federal Interagency Forum on aging-related statistics. Washington, DC: U.S. Government Printing Office; March 2008;www.agingstats.gov
  4. Public Health and Aging: trends in aging—United States and Worldwide. JAMA. 2003;289:1371–1373
  5. Greenwald DA. Aging, the gastrointestinal tract, and the risk of acid-related disease. Am J Med. 2004;117:8S–13S
  6. Saffrey MJ. Ageing of the enteric nervous system. Mech Ageing Dev. 2004;125:899–906
  7. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol. 1995;90:1053–1057
  8. Abid S, Mumtaz K, Jafri W, Hamid S, Abbas Z, Shah HA, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005;37:740–744
  9. Boyce HW. Drug-induced esophageal damage: diseases of medical progress. Gastrointest Endosc. 1998;47:547–550
  10. Jain V, Pitchumoni CS. Gastrointestinal side effects of prescription medications in the older adult. J Clin Gastroenterol. 2009;43:103–110
  11. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf. 2000;22:237–249
  12. Graham DY. What gastroenterologist should know about the gastrointestinal safety profile of biphosphonates. Dig Dis Sci. 2002;47:1665–1678
  13. Zhu H, Pace F, Sangaletti O, Bianchi Porro G. Features of symptomatic gastroesophageal reflux in elderly patients. Scand J Gastroenterol. 1993;28:235–238
  14. Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev. 1998;7:749–756
  15. Clark-Vetri RJ. Management of chemotherapy-induced emesis. Pharm Times. 1999;65:78–85
  16. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593
  17. Dominick KL, Ahern FM, Gold CH, Heller DA. Gender differences in NSAID use among older adults with osteoarthritis. Ann Pharmacother. 2003;37:1566–1571
  18. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol. 1999;13:119–122
  19. Jones JIW, Hawkey CJ. Physiology and organ related pathology of the elderly: stomach ulcers. Best Pract Res Clin Gastroenterol. 2001;15:943–961
  20. Lanza FL, Chan FKL, Quigley EMM, the Practice Parameters Committee of the American College of Gastroenterology . Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–738
  21. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and non-steroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006;4:130–142
  22. Pilotto A, Salles N. Helicobacter pylori infection in geriatrics. Helicobacter. 2002;7(Suppl. 1):56–62
  23. Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol Clin North Am. 2009;38:289–3003
  24. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005;9:1–152
  25. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323–332
  26. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59:1097–1104
  27. Papatheodoridis GV, Archimandritis AJ. The role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. World J Gastroenterol. 2005;11:3811–3816
  28. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103:2908–2918
  29. Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133:790–798
  30. Rahme E, Barkun AN, Toubouti Y, Scalera A, Rochon S, Lelorier J. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?. Arthritis Rheum. 2007;57:748–755
  31. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol. 2001;52:185–192
  32. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–1517
  33. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–113
  34. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507–515
  35. Khalique SC, Chenq-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev. 2009;17:198–200
  36. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111:4871–4879
  37. Fortun PJ, Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the intestine. Curr Opin Gastroenterol. 2005;21:169–175
  38. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–141
  39. Thiefin G, Beaugerie L. Toxic effects of nonsteroidal anti-inflammatory drugs in the small bowel, colon and rectum. Joint Bone Spine. 2005;72:286–294
  40. Drozdowski L, Thomson AB. Aging and the intestine. World J Gastroenterol. 2006;12:7578–7584
  41. Andrès E, Kaltenbach G, Perrin AE, Kurtz JE, Schlienger JL. Food-cobalamin malabsorption in the elderly. Am J Med. 2002;113:351–352
  42. Conrad ME, Umbreit JN. Iron absorption and transport – an update. Am J Hematol. 2000;64:287–298
  43. Peterson DE, Keefe DM, Hutchins RD, Schubert MM. Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Support Care Cancer. 2006;14:499–504
  44. Triantafyllou K, Dervenoulas J, Tsirigotis P, Ladas SD. The nature of intestinal mucositis: a video capsule endoscopy study. Support Care Cancer. 2008;16:1173–1178
  45. Faucheron J-L, Parc R. Non-steroidal anti-inflammatory drug-induced colitis. Int J Colorectal Dis. 1996;11:99–101
  46. Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case–control study. Ann Coll Surg Engl. 2002;84:93–96
  47. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther. 2004;19:755–764
  48. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhea in the elderly. Drugs Aging. 1998;13:245–253
  49. Kelly CP, laMont JT. Clostridium difficile – more difficult than ever. N Engl J Med. 2008;359:1932–1940
  50. Dial S, Delaney C, Scheneider V, Suissa S. Proton pump inhibitor use and the risk of community-acquired Clostridium difficile-associated disease defined by prescription of oral vancomycin. CMAJ. 2006;175:745–748
  51. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472
  52. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–557
  53. Fernádez-Banãrez F. Epidemiology of microscopic colitis. In:  Colombel JF,  Jewell DP,  Pena AS,  Tromm A,  Waren BF editor. Colitis: diagnosis and therapeutic strategies. Falk symposia series. vol. 147:Dordrecht: Springer; 2006;p. 25–32
  54. Fernández-Bañares F, Esteve M, Espinós JC, Rosinach M, Forné M, Salas A, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007;102:324–330
  55. Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22:277–284
  56. Brandt LJ. Intestinal ischaemia. In:  Feldman M,  Friedman LS,  Brandt LJ editor. Sleisenger and Fordtran's gastrointestinal and liver disease. 8th ed. Philadelphia, PA: W.B. Saunders Co.; 2006;p. 2563–2585
  57. Hass DJ, Kozuch P, Brandt LJ. Pharmacologically mediated colon ischaemia. Am J Gastroenterol. 2007;102:1765–1780
  58. Chang CY, Schiano TD. Drug hepatotoxicity. Aliment Pharmacol Ther. 2007;25:1135–1151
  59. Almdal TP, Sorensen TIA, The Danish Association for the Study of the Liver . Incidence of parenchymal liver disease in Denmark, 1981 to 1985: analysis of hospitalization registry data. Hepatology. 1990;13:650–655
  60. Hayes BD, Klein-Schwartz W, Barrueto F. Polypharmacy and the geriatric patient. Clin Geriatr Med. 2007;23:371–390
  61. Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing. 1999;28:29–33
  62. Le Couteur DG, Cogger VC, Markus AM, Harvey PJ, Yin ZL, Ansselin AD, et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology. 2001;33:537–543
  63. McLean AJ, Cogger VC, Chong GC, Warren A, Markus AM, Dahlstrom JE, et al. Age-related pseudocapillarization of the human liver. J Pathol. 2003;200:112–117
  64. Wrighton SA, Vandenbranden M, Ring BJ. The human drug metabolizing cytochromes P450. Pharmacokinet Biopharm. 1996;24:461–473
  65. Deleve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am. 1995;24:787–810
  66. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275–283
  67. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1–21
  68. Sandson NB. Appendix A. P450 tables. In: Drug interactions casebook. The cytochrome P450 system and beyond. Washington, DC: American Psychiatric Publishing Inc.; 2003;p. 251–269
  69. Sanz N, Díez-Fernández C, Alvarez AM, Fernández-Simón L, Cascales M. Age-related changes on parameters of experimentally-induced liver injury and regeneration. Toxicol Appl Pharmacol. 1999;154:40–49
  70. Junaidi O, Di Bisceglie AM. Aging liver and hepatitis. Clin Geriatr Med. 2007;23:889–903
  71. Onji M, Fujioka S, Takeuchi Y, Takaki T, Osawa T, Yamamoto K, et al. Clinical characteristics of drug-induced liver injury in the elderly. Hepatol Res. 2009;39:546–552
  72. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14:6774–6785
  73. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006;10:207–217
  74. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6:673–684
  75. Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. BMJ. 1982;284:1372
  76. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1993;27:228–231
  77. Andrade RJ, Lucena MI, Fernández MC, Vega JL, García-Cortés M, Casado M, et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol. 2002;14:887–890
  78. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23:197–213
  79. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44:850–856
  80. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489–499
  81. Polson JE. Hepatotoxicity due to antibiotics. Clin Liver Dis. 2007;11:549–561
  82. Pugh AJ, Barve AJ, Falkner K, Patel M, McClain CJ. Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis. 2009;13:277–294
  83. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology. 1997;25:103–107
  84. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8:599–606
  85. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009;104:356–362
  86. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med. 1988;85:771–774
  87. Lewis JH, Schiff ER. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol. 1988;88:1337–1345

PII: S1521-6918(10)00018-1

doi: 10.1016/j.bpg.2010.02.004

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 203-215 , April 2010

Article Tools